Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- JCR, Alexion Tie Up to Develop Oligonucleotide Therapeutics
December 21, 2023
- JCR, Takeda Wind Up Collab on Gene Therapy Research
December 21, 2023
- Shionogi’s Novel Antibiotic Fetroja Now Available in Japan
December 21, 2023
- Chugai’s Corporate VC Arm to Go Live in 2024
December 20, 2023
- Daiichi Sankyo Launch 2 PIII Breast Cancer Trials for TROP2 ADC
December 20, 2023
- Xocova Rights Sub-Licensed to Juniper in Singapore: Shionogi
December 20, 2023
- Otsuka Bags European Commercial Rights to Ionis’ HAE Drug
December 20, 2023
- Ono, EVQLV Link Arms on AI-Powered Antibody Drug Development
December 20, 2023
- Sanofi Files High-Dose Quadrivalent Flu Vaccine in Japan
December 20, 2023
- DyDo Pharma Files Its 1st Drug, LEMS Treatment for Japan Market
December 19, 2023
- EMA Endorses GHIT-Funded Schistosomiasis Therapy
December 19, 2023
- Dupixent 200 mg Syringe Now Available in Japan: Sanofi
December 19, 2023
- Shionogi, Sobi Ink Fetcroja Distribution Pact for 13 European Countries
December 19, 2023
- Shionogi Kicks Off PIII Booster Trial for XBB1.5 COVID Vaccine in Japan
December 19, 2023
- Takeda’s Hyqvia Gets EU Panel Backing for CIDP Maintenance Therapy
December 19, 2023
- Padcev/Keytruda Combo Nabs FDA Nod for 1st Line Bladder Cancer
December 19, 2023
- Eisai Files Tasurgratinib for Biliary Tract Cancer in Japan
December 19, 2023
- Terumo’s Next CEO Resolved to Drive Biologics Forward, Fulfill Diverse Demands
December 18, 2023
- Eisai CEO Anticipates Leqembi Approval in Europe and China by March
December 18, 2023
- Alecensa Filed for Adjuvant Therapy for ALK-Positive NSCLC: Chugai
December 18, 2023
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…